z-logo
Premium
Hypomagnesemia and incidence of osteoradionecrosis in patients with head and neck cancers
Author(s) -
Liu Wenli,
Qdaisat Aiham,
Zhou Shouhao,
Fuller Clifton D.,
Ferrarotto Renata,
Guo Ming,
Lai Stephen Y.,
Cardoso Richard,
Mohamed Abdallah S. R.,
Lopez Gabriel,
Narayanan Santhosshi,
Dijk Lisanne V.,
Cohen Lorenzo,
Bruera Eduardo,
Yeung SaiChing J.,
Hanna Ehab Y.
Publication year - 2021
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.26510
Subject(s) - osteoradionecrosis , medicine , hypomagnesemia , head and neck cancer , carboplatin , radiation therapy , cancer , induction chemotherapy , surgery , mucositis , incidence (geometry) , epidermoid carcinoma , chemotherapy , oncology , cisplatin , physics , materials science , optics , magnesium , metallurgy
Background We aimed to determine whether hypomagnesemia predicts osteoradionecrosis development in patients with squamous cell carcinoma of the oropharynx and oral cavity who received platinum‐based concurrent chemoradiation with or without induction therapy. Methods We reviewed data from patients with head and neck cancers who had undergone chemoradiation with weekly cisplatin/carboplatin between January 1, 2010 and December 31, 2014 at our institution. Pathologic features, laboratory test results, disease stage, and social histories were recorded. The association between hypomagnesemia and osteoradionecrosis was analyzed controlling for known confounding factors. Results Hypomagnesemia during cancer treatment was associated with osteoradionecrosis development (HR = 2.72, P = .037) independent of total radiation dose (HR = 1.07, P = .260) and smoking history (HR = 2.05, P = .056) among the patients who received platinum‐based induction chemotherapy followed by concurrent chemoradiation. Conclusions Hypomagnesemia was predictive of the development of osteoradionecrosis in patients with cancers of the oropharynx and oral cavity receiving platinum‐based induction followed by concurrent chemoradiation.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here